Geisinger

Geisinger | September 27, 2017

Geisinger and pharmaceutical partner Boehringer Ingelheim will collaborate with pharmaceutical giant Eli Lilly to develop a risk-prediction model for three critical health outcomes commonly associated with type 2 diabetes: cardiovascular death, kidney failure and hospitalization for heart failure....

MedCity News | May 23, 2018

If you have a genetic mutation that increases your risk for a treatable medical condition, would you want to know? For many people, the answer is yes. But such information is not commonly part of routine primary care. For patients at Geisinger Health System, that could soon change. Starting in the next month or so, the Pennsylvania-based system will offer DNA sequencing to 1,000 patients, with the goal to eventually extend the offer to all 3 million Geisinger patients....

Fierce Healthcare | May 08, 2018

It wasn't that long ago that the cost of DNA sequencing was measured in the millions of dollars. Even a few years ago, when the cost fell closer to a few thousand dollars, it was largely used for research purposes or reactively as a tool for patients who'd already fallen ill. Now, Geisinger President and CEO David Feinberg, M.D., said the time and cost is finally right to make whole exome sequencing a "routine" part of screening for patient diseases....

EHRIntelligence | January 16, 2020

Eighty-four percent of EHR users are dissatisfied with the technical service and basic software account support from current EHR and HIT vendors, according to a 2020 Black Book Research survey. Since the HITECH Act was signed into law in 2009, EHRs have not only been more prevalent, but they have continued to change and evolve. However, technical service from EHR vendors hasn’t kept up with the constant change, according to high-level hospital tech managers. Healthcare software support is ...